Nettle Raises $4.8M

IMMIX

Stablecoin liquidity is concentrated in dollars. IMMIX is an AI-native trading firm that makes markets in non-USD stablecoin FX, trading as principal. Outside dollar markets, fragmented liquidity turns a single conversion into multiple FX legs, intermediary transfers, prefunding and stacked desk fees. A thin pair has too little data to price on its own, so most desks quote the dollar pairs and leave the rest. We develop and apply state-of-the-art deep learning to close that gap. Models forecast market states for 10,000+ instruments from 30+ sources, so the desk can price a market into a counterparty where no direct market exists. A portfolio optimiser sets price, hedge and execution together across the whole book. Models forecast, estimate and inform. The desk prices, quotes, holds and hedges. One desk. Three kinds of partner. Payment firms: one FX transaction per payment, priced and executed as principal. Stablecoin issuers: a direct market for your asset, built and operated by the desk. Venues and platforms, including FX brokers and investment platforms: two-sided principal liquidity on the pairs your venue lists. Founded by Andrew Mann, PhD and David Twomey, PhD. Team previously at Virtu Financial, J.P. Morgan, DV Trading, UBS, Morgan Stanley, ICE, Bank of England, UCL and the University of Cambridge. Backed by MassMutual Ventures, Ripple, Crane Venture Partners, Portfolio Ventures and BTSE. 10,000+ instruments modelled: unique instruments in the IMMIX instrument model, as of 22 August 2026; not tradable or offered instruments. 30+ sources: integrated market-data sources; not all simultaneously live or used for every market. $25B+ traded: cumulative traded notional through IMMIX infrastructure, as of 22 August 2026; infrastructure history, not desk volume. Better markets begin with better models.

Universal Quantum

A quantum computer harnesses the fundamental forces that govern the physical world. It can efficiently model complex systems in ways that would take the best classical computer millions of years, and so help revolutionise drug design, climate modelling, battery chemistry, and many other vital processes. But to achieve all this, we need to make quantum computers work reliably at scale. We started Universal Quantum to meet this challenge - because we believe that by doing so, we can help solve the most difficult problems faced by humanity. We’re following a pragmatic, engineering-based roadmap to build a device that is useful in the real world: a quantum computer that has utility. Every approach we take, every solution we devise, is geared towards this goal.

Cori Clinical

Cori Clinical: The intelligence layer for accelerating clinical trials. We turn clinical trial insight and organisational experience into a living blueprint of the trial, from the initial trial idea to first patient in. We’re working with leading biotechs, CROs, and research institutions, backed by operators in life sciences and AI - to empower clinical teams to move faster, stay aligned, and raise quality without compromising compliance. Cori provides one workspace for the entire trial start-up: research, design, authoring, review, protocol modifications. Cori is AI-guided: it drafts, your team decides. So the science never waits on the process.